SG10201912556VA - HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) - Google Patents

HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Info

Publication number
SG10201912556VA
SG10201912556VA SG10201912556VA SG10201912556VA SG10201912556VA SG 10201912556V A SG10201912556V A SG 10201912556VA SG 10201912556V A SG10201912556V A SG 10201912556VA SG 10201912556V A SG10201912556V A SG 10201912556VA SG 10201912556V A SG10201912556V A SG 10201912556VA
Authority
SG
Singapore
Prior art keywords
hptp
ptp
target
monoclonal antibodies
humanized monoclonal
Prior art date
Application number
SG10201912556VA
Other languages
English (en)
Inventor
Kevin Peters
Michael Allen Flynn
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of SG10201912556VA publication Critical patent/SG10201912556VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10201912556VA 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) SG10201912556VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364381P 2016-07-20 2016-07-20
US201662377072P 2016-08-19 2016-08-19

Publications (1)

Publication Number Publication Date
SG10201912556VA true SG10201912556VA (en) 2020-02-27

Family

ID=60988231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912556VA SG10201912556VA (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
SG11201900464TA SG11201900464TA (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201900464TA SG11201900464TA (en) 2016-07-20 2017-07-19 HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)

Country Status (13)

Country Link
US (6) US10253094B2 (de)
EP (1) EP3487518A4 (de)
JP (3) JP7107914B2 (de)
KR (1) KR20190031246A (de)
CN (1) CN109715189A (de)
AU (1) AU2017299581A1 (de)
BR (1) BR112019001206A2 (de)
CA (1) CA3030298A1 (de)
IL (1) IL263936A (de)
MX (1) MX2019000727A (de)
PH (1) PH12019500145A1 (de)
SG (2) SG10201912556VA (de)
WO (1) WO2018017714A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008012991A (es) * 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8999325B2 (en) * 2011-10-13 2015-04-07 Aerpio Therapeutics, Inc Treatment of ocular disease
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
EP3471767A4 (de) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenzavirus-hämagglutinin-proteine und verwendungen davon
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
EP3606555A4 (de) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon
WO2020068653A1 (en) * 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
AU2019392090A1 (en) * 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
CA3137160A1 (en) * 2019-04-24 2020-10-29 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
ES2199804T3 (es) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1046715A1 (de) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaktion zwischen Vaskularendothelialproteintyrosinphosphatase und Angiopoietinrezeptor Tie-2
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
CN1318093C (zh) 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
US20050260132A1 (en) 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
EP1450852B1 (de) 2001-12-04 2007-01-17 DeveloGen Aktiengesellschaft Ptp10d nukleinsäuren und peptide in der regulation von energie-homeostase
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US20040023880A1 (en) 2002-05-03 2004-02-05 Gale Nicholas W. Methods of inducing formation of functional and organized lymphatic vessels
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
CA2599606A1 (en) * 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
JP2009510102A (ja) 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
WO2007068895A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
WO2007087457A2 (en) 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
NZ571208A (en) * 2006-03-10 2011-12-22 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
MX2008012991A (es) 2006-04-07 2008-10-17 Procter & Gamble Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos.
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009154026A1 (ja) * 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CN108635350A (zh) 2009-01-12 2018-10-12 爱尔皮奥治疗有限公司 治疗血管渗漏综合征的方法
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
WO2010097800A1 (en) 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
EP2411412B1 (de) * 2009-03-24 2015-05-27 Teva Biopharmaceuticals USA, Inc. Humanisierte antikörper gegen licht und anwendungen davon
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP3511023A1 (de) 2009-12-02 2019-07-17 Imaginab, Inc. J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CA2818215C (en) 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CN103402582A (zh) 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法
US8846042B2 (en) * 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
US8999325B2 (en) * 2011-10-13 2015-04-07 Aerpio Therapeutics, Inc Treatment of ocular disease
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2014203183A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
EP3010525A1 (de) 2013-06-20 2016-04-27 Novartis AG Verwendung eines vegf-antagonisten bei der behandlung von choroidaler neovaskularisation
US20160159893A1 (en) 2013-07-11 2016-06-09 Gabriela Burian Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
CN105377891A (zh) 2013-07-11 2016-03-02 诺华股份有限公司 Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
EP3057990B1 (de) 2013-10-18 2019-09-04 Regeneron Pharmaceuticals, Inc. Zusammensetzungen mit einer kombination aus einem vegf-antagonisten und einem anti-ctla-4-antikörper
RU2019118984A (ru) * 2014-01-10 2019-08-06 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
EP3116503A4 (de) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta-hemmer
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
TW201619194A (zh) 2014-09-16 2016-06-01 歐把科學股份有限公司 特異性結合至人類vasa蛋白質的抗體、抗體製劑、經分離核酸分子、細胞及分離表現vasa蛋白質的細胞的方法
US20160082129A1 (en) * 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
BR112017020986A2 (pt) 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
EP3341021A4 (de) 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. Anti-alk-antikörper und verfahren zur verwendung davon
TWI748962B (zh) 2015-09-23 2021-12-11 美商建南德克公司 抗ｖｅｇｆ抗體之最佳化變異體
JP6959924B2 (ja) 2015-09-23 2021-11-05 エアーピオ ファーマシューティカルズ， インコーポレイテッド Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)

Also Published As

Publication number Publication date
JP2022101694A (ja) 2022-07-06
SG11201900464TA (en) 2019-02-27
US20190077862A1 (en) 2019-03-14
CN109715189A (zh) 2019-05-03
US10253094B2 (en) 2019-04-09
WO2018017714A1 (en) 2018-01-25
US20200239567A1 (en) 2020-07-30
US11180551B2 (en) 2021-11-23
JP7107914B2 (ja) 2022-07-27
EP3487518A4 (de) 2020-08-12
US20230134885A1 (en) 2023-05-04
BR112019001206A2 (pt) 2019-06-25
AU2017299581A1 (en) 2019-01-17
US20190077863A1 (en) 2019-03-14
EP3487518A1 (de) 2019-05-29
CA3030298A1 (en) 2018-01-25
US10604569B2 (en) 2020-03-31
JP2019531259A (ja) 2019-10-31
PH12019500145A1 (en) 2019-07-29
KR20190031246A (ko) 2019-03-25
US20180022804A1 (en) 2018-01-25
JP2020180156A (ja) 2020-11-05
US20200270342A1 (en) 2020-08-27
US10597452B2 (en) 2020-03-24
US11136389B2 (en) 2021-10-05
MX2019000727A (es) 2019-05-02
IL263936A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
ZA201803874B (en) Humanized anti-cd73 antibodies
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
ZA201900353B (en) Anti-pd-l1 antibodies
IL263936A (en) Humanized monoclonal antibodies targeting hptp-beta)ve-ptp)
IL262295B1 (en) Antibodies against pd–l1
IL256562A (en) Human cd3 antibodies or chimeras
HK1258375A1 (zh) 人源化抗-cll-1抗體
EP3294766C0 (de) Humanized antibody or fragment thereof specific for cd3
IL283812A (en) Humanized antibody against human pd–1
EP3532489A4 (de) Neutralisierende monoklonale anti-tl1a-antikörper
IL256579A (en) Human antibodies
EP3441086A4 (de) Monoklonaler anti-pd-1-antikörper
IL262776A (en) Human anti-il-1r3 antibodies
IL282756A (en) Humanized antibodies against SIRPα
GB201820554D0 (en) BTLA antibodies
EP3567053A4 (de) Monoklonaler anti-claudin-2-antikörper
EP3490601A4 (de) Monoklonale anti-annexin-a2-antikörper
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
IL279823A (en) Antibodies cultured against PSMA
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB201820006D0 (en) Humanised anti-IL17BR antibody
EP3690051A4 (de) Monoklonaler anti-ckap4-antikörper
EP3362093A4 (de) Heparanase-neutralisierende monoklonale antikörper
GB201511196D0 (en) Monoclonal antibodies
HK1255635A1 (zh) 人源化或嵌合的cd3抗體